{"id":"anti-vegf-agent","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Hypertension"},{"rate":"15–30%","effect":"Proteinuria"},{"rate":"5–15%","effect":"Bleeding"},{"rate":"5–10%","effect":"Thrombotic events"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"10–20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4802227","moleculeType":"Small molecule","molecularWeight":"274.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VEGF is a key driver of neovascularization in tumors and certain ocular diseases. By neutralizing VEGF or its receptors, anti-VEGF agents starve tumors of blood supply and reduce pathological vessel growth. This class includes monoclonal antibodies (e.g., bevacizumab), receptor tyrosine kinase inhibitors, and other biologics targeting the VEGF pathway.","oneSentence":"Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:07.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"},{"name":"Wet age-related macular degeneration"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT06890026","phase":"","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve","enrollment":742},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT06083844","phase":"PHASE2","title":"Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-12-12","conditions":"Ovarian Cancer","enrollment":20},{"nctId":"NCT05214482","phase":"PHASE1, PHASE2","title":"A Study of AK112 in Advanced Malignant Tumors","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-01-22","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT07446452","phase":"PHASE2","title":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2-low Breast Cancer","enrollment":37},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT07133438","phase":"PHASE4","title":"Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-08-01","conditions":"Retinal Vein Occlusion (RVO)","enrollment":120},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT05488522","phase":"PHASE1","title":"SBRT With Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT04109924","phase":"PHASE2","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-27","conditions":"Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT06709339","phase":"PHASE4","title":"Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)","status":"RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2025-08-06","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":120},{"nctId":"NCT07393555","phase":"PHASE2","title":"Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-08-07","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT01217931","phase":"PHASE2","title":"Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-19","conditions":"Kidney Cancer","enrollment":180},{"nctId":"NCT07368023","phase":"","title":"A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Medical Center Lihuili Hospital","startDate":"2026-01-25","conditions":"Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":83},{"nctId":"NCT07333287","phase":"PHASE2","title":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2026-02-01","conditions":"Pancreatic Cancer Liver Metastases, Immunotherapy-naive","enrollment":38},{"nctId":"NCT07310836","phase":"","title":"A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Medical Center Lihuili Hospital","startDate":"2025-12-20","conditions":"Hepatocellular Carcinoma, Liver Transplantation","enrollment":300},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06856837","phase":"PHASE2","title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-10-27","conditions":"Metastatic Colorectal Cancer","enrollment":140},{"nctId":"NCT06121180","phase":"PHASE2","title":"Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-04","conditions":"Metastatic Uveal Melanoma","enrollment":32},{"nctId":"NCT01081262","phase":"PHASE3","title":"Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-12","conditions":"Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma","enrollment":50},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT07111520","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-09-22","conditions":"Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT07204262","phase":"","title":"Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xu Yong, MD","startDate":"2018-01-01","conditions":"Liver Cancer","enrollment":379},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT07187284","phase":"PHASE1, PHASE2","title":"EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-09-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT05200364","phase":"PHASE1","title":"A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2022-03-22","conditions":"Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer","enrollment":58},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT04567550","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-11-20","conditions":"Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)","enrollment":139},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer","enrollment":140},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT07106268","phase":"","title":"Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2023-03-01","conditions":"Retinal Vein Occlusion","enrollment":100},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT07065435","phase":"PHASE2","title":"RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2 + Breast Cancer","enrollment":74},{"nctId":"NCT07062055","phase":"PHASE2","title":"BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-25","conditions":"Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases","enrollment":46},{"nctId":"NCT04356729","phase":"PHASE2","title":"A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elizabeth Buchbinder, MD","startDate":"2020-08-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma","enrollment":30},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56},{"nctId":"NCT07007767","phase":"PHASE2","title":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-15","conditions":"Colorectal Cancer Metastatic","enrollment":32},{"nctId":"NCT03762018","phase":"PHASE3","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-30","conditions":"Pleural Mesothelioma Malignant Advanced","enrollment":401},{"nctId":"NCT06944470","phase":"PHASE2","title":"JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-04-20","conditions":"NSCLC","enrollment":76},{"nctId":"NCT06902207","phase":"","title":"Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-10","conditions":"Intraocular Inflammation","enrollment":6053},{"nctId":"NCT03786796","phase":"PHASE2","title":"Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-06-03","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT05698329","phase":"PHASE1","title":"Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AiViva BioPharma, Inc.","startDate":"2023-03-02","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema","enrollment":19},{"nctId":"NCT04171141","phase":"PHASE1","title":"Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-11-19","conditions":"Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas","enrollment":79},{"nctId":"NCT05093374","phase":"PHASE4","title":"Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2021-03-01","conditions":"Exudative Macular Degeneration","enrollment":290},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT06448364","phase":"PHASE1","title":"A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-05-09","conditions":"Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":4},{"nctId":"NCT06665087","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":110},{"nctId":"NCT01621568","phase":"PHASE2","title":"Sunitinib for Advanced Thymus Cancer Following Earlier Treatment","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-15","conditions":"Thymoma, Thymus Neoplasms","enrollment":56},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT06580574","phase":"PHASE2","title":"Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-08-13","conditions":"Gastric Cancer, Colon Cancer, MSI-H","enrollment":38},{"nctId":"NCT06331169","phase":"PHASE1","title":"Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-31","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT04469595","phase":"PHASE4","title":"A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimera Sciences","startDate":"2020-08-31","conditions":"Diabetic Macular Edema","enrollment":300},{"nctId":"NCT04049266","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2019-10-08","conditions":"Wet Macular Degeneration","enrollment":559},{"nctId":"NCT04411693","phase":"PHASE4","title":"Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-04-10","conditions":"Diabetic Macular Edema","enrollment":23},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT03321513","phase":"PHASE3","title":"DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2017-12-07","conditions":"Diabetic Macular Edema","enrollment":270},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT04304755","phase":"PHASE2","title":"Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-10-25","conditions":"Neovascular Age-related Macular Degeneration","enrollment":40},{"nctId":"NCT06317922","phase":"NA","title":"Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF Injections","status":"RECRUITING","sponsor":"Francesco Bandello","startDate":"2024-02-05","conditions":"Dry Eye Syndromes","enrollment":60},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT04674254","phase":"PHASE4","title":"Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-30","conditions":"Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy","enrollment":43},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06119347","phase":"","title":"Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs","enrollment":1581},{"nctId":"NCT02924311","phase":"","title":"Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-21","conditions":"Diabetic Retinopathy","enrollment":402},{"nctId":"NCT02279537","phase":"","title":"Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-02","conditions":"Wet Macular Degeneration","enrollment":593},{"nctId":"NCT06099821","phase":"PHASE2","title":"KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-10-25","conditions":"Digestive System Cancers","enrollment":39},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT03334864","phase":"","title":"Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-11-03","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":5000},{"nctId":"NCT05156021","phase":"NA","title":"A Study on the Treatment Strategy of NVG Secondary to PDR","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2021-12-12","conditions":"Neovascular Glaucoma, Proliferative Diabetic Retinopathy","enrollment":39},{"nctId":"NCT03961698","phase":"PHASE2","title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Breast Cancer, Renal Cell Carcinoma","enrollment":91},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT04305106","phase":"PHASE3","title":"Bevacizumab in Patients With Severe Covid-19","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-01-12","conditions":"COVID-19 Pneumonia","enrollment":588},{"nctId":"NCT04524910","phase":"","title":"A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-06-16","conditions":"Myopic Choroidal Neovascularization","enrollment":28},{"nctId":"NCT05903456","phase":"PHASE2","title":"Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT02623023","phase":"NA","title":"Prophylaxis for Anti-VEGF-induced IOP Elevation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2019-01-01","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT03066258","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial","status":"COMPLETED","sponsor":"REGENXBIO Inc.","startDate":"2017-03-29","conditions":"Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":42},{"nctId":"NCT04454905","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT05587062","phase":"PHASE3","title":"Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2019-10-01","conditions":"Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":168},{"nctId":"NCT03963596","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Pathologic Myopia","enrollment":122},{"nctId":"NCT02425501","phase":"","title":"Special Drug Use Investigation of EYLEA for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-20","conditions":"Macular Edema","enrollment":646},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"EYELID PTOSIS"}],"_approvalHistory":[],"publicationCount":392,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cohort 1 - Quantitative","Cohort 2 - Qualitative"],"phase":"marketed","status":"active","brandName":"anti-VEGF agent","genericName":"anti-VEGF agent","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}